Panion presents at Animal Health Investment Europe, in London 26-27 February 2019
Panion Animal Health AB develops an innovative treatment for epilepsy in dogs and has just started the clinical phase. The product in development is based on the gene therapy platform for human epilepsy from CombiGene AB. Panion has been selected as one of 24 finalist companies to present at the 2019 Animal Health Investment Innovation Showcase. Panion’s chairman of the board, Lars Thunberg, and CEO, Anja Holm, will address the audience with a focus on the commercial elements of Panion’s business and plans in the programme on translational technology from human-to-veterinary pharma.